Ark Therapeutics has had three of its products accepted for inclusion in the new UK National Health Service's Supply Chain Advanced Wound Care and Topical Negative Pressure Therapy Contract.
The three products are: Kerraboot, a boot-shaped dressing that can be quickly and easily changed when protecting foot and leg ulcers; Flaminal, for protecting from infections without toxicity to human cells; and Kerraped, medical footware for patients with ulcers.
The new NHS contract is designed to promote best practice and cost effectiveness in wound care by encouraging all NHS Trusts in England and Wales to use and purchase the same brands of products, as listed by the contract.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze